EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Platelet transfusion tolerization by liver membrane treatment



Platelet transfusion tolerization by liver membrane treatment



Transplantation 28(2): 96-99



A nontoxic murine model has been developed in which sensitization to allogeneic platelet transfusions in adults can be prevented. This model is based upon allogeneic liver membrane (LM) induction of specific humoral tolerance to major histocompatibility alloantigens. In normal mice of the C3H background, syngeneic and H-2-incompatible congeneic platelets had a t1/2 = 15 +/- 3 hr; for mice of the C57BL background, the comparable t1/2 was 33 +/- 6 hr. Platelets of C3H background transfused into C57BL background recipients, and vice versa, had t1/22 midway between, 24 +/- 3 and 24 +/- 2 hr, respectively. These data suggest genetically determined variation in normal platelet survival. In passively immunized C3H background mice, the t1/2 was decreased to 10 +/- 2 hr. In C57BL background mice actively immunized i.p. with allogeneic lymphoid cells, t1/2 was decreased to 18 +/- 4 hr. When allogeneic LM was given concomitantly with the allogeneic cells, however, sensitization to foreign H-2 antigens was blocked, and survival of both C3H and C57BL background allogeneic platelets remained normal. These data demonstrate that in this free cell allograft system LM treatment is a safe and effective method for preventing adult sensitization to allogeneic platelets.

(PDF same-day service: $19.90)

Accession: 006135191

Download citation: RISBibTeXText

PMID: 483363

DOI: 10.1097/00007890-197908000-00004



Related references

Current studies in hematology and blood transfusion no 54 platelet membrane in transfusion medicine second canadian workshop and conference on platelet serology ottawa ontario canada january 9 10 1987. 1988

Platelet transfusion in neonatal extracorporeal membrane oxygenation Comparison of apheresis platelets and platelet concentrates. Blood 92(10 SUPPL 1 PART 1-2): 566A-567A, Nov 15, 1998

Evaluation of hemostatic effectiveness of infusible platelet membrane in rabbits as a potential substitute for platelet transfusion. 2012

Infusible platelet membrane as a platelet substitute for transfusion: an overview. Blood Transfusion 11(3): 337-342, 2014

Platelet membrane in transfusion medicine. Second Canadian Workshop and Conference on Platelet Serology. Ottawa, January 9 and 10, 1987. Proceedings. Current Studies in Hematology and Blood Transfusion: 1-153, 1988

Romiplostim treatment allows for platelet transfusion-free liver transplantation in pediatric thrombocytopenic patient with primary sclerosing cholangitis. Pediatric Transplantation 18(6): E212-E215, 2015

Successful treatment of platelet transfusion refractoriness The use of platelet transfusions matched for both human leucocyte antigens and human platelet alloantigens in alloimmunized patients with leukaemia. European Journal of Haematology 60(2): 112-118, 1998

Successful treatment of platelet transfusion refractoriness: The use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia. European Journal of Haematology 60(2): 112-118, 1998

Platelet transfusion can be related to liver regeneration after living donor liver transplantation. World Journal of Surgery 34(5): 1052-1058, 2010

Platelet transfusion improves liver function in patients with chronic liver disease and cirrhosis. Tohoku Journal of Experimental Medicine 229(3): 213-220, 2013

Mathematical modeling of platelet survival with implications for optimal transfusion practice in the chronically platelet transfusion-dependent patient. Transfusion 38(7): 637-644, 1998

Sphingosine-phosphate content in the plasma of platelet concentrates correlates with poor platelet increments after transfusion and with occurrences of transfusion reactions in patients. American Journal of Hematology 57(3): 261-262, 1998

HLA compatibility and transfusion of a platelet concentrate--a necessary prerequisite for the successful transfusion of platelet concentrates in patients with HLA antibodies. Casopis Lekaru Ceskych 125(12): 363-365, 1986

Prevention of platelet transfusion refractoriness and HLA alloimmunization by leukocyte filtered platelet transfusion: a meta analysis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae 33(4): 412-420, 2013